GSK TSKF Establishes Oral Care R&D Center In Beijing
This article was originally published in PharmAsia News
Executive SummarySino-American Tianjin Smith Kline & French Laboratories (TSKF) announced Jan. 22 the establishment of their China Business Innovation Center and Oral Care R&D Center
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.